NCT06107114尚未招募2 期
An Open, Single-center, Phase II Trial of Cetuximab+Zimberelimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Xuekui Liu1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2023年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This study is a single arm phase ll trial including 52 patients with T2N2-3M0#T3-4N0-3M0 (III-V) head and neck squamous cell carcinoma(HNSCC) eligible forresection, who receive Cetuximab+ Zimberelimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperative administration of Cetuximab+ Zimberelimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma(HNSCC) who are about to undergo surgery.
详细描述
In this study, eligible subject will be enrolled into study arm to accept study treatment objective response rate will be the primary outcome measures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed primary head and neck squamous cell carcinoma confirmed by histology and/or cytology (excluding diagnostic therapy).
- •Clinical stage:T2N2-3M0,T3-4N0-3M0 (AJCC 8th editionstaging).
- •Age: 18 to 70 years.
- •PS score (see Appendix Table 1; performance status score of 0 or 1).
- •Patients evaluated by a head and neck oncologist as resectable with no distant metastases.
- •Patients with at least one measurable lesion according to RECIST version 1.1 criteria.
- •Patients' toxicities assessed according to CTCAE version 4.03 criteria.
- •Patients with normal organ function (heart,brain, lungs, kidneys) and suitable for surgery:
- •Hematology: White blood cells ≥ 3500/μL,neutrophils ≥1,800/pL, hemoglobin ≥ 9 g/dL, platelets ≥100,000/μL;
- •Liver function: Bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin levels ≤ 3 times ULN can be included), AST and ALT ≤3 times ULN, alkaline phosphatase ≤ 3 times ULN; albumin ≥ 3 g/dL; c.Renal function: Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL/min according to Cockcroft-Gault formula.
- •Patients have signed an informed consent form, are willing and able to comply with the study's visit, treatment plan, laboratory tests, and other study procedures.
排除标准
- •History of severe hypersensitivity reactions to components of other monoclonal antibodies, CTLA4, or PD-1 antibodies.
- •Patients with known or suspected autoimmune diseases, including dementia and epileptic seizures.
- •Recurrence, distant metastasis, or the inability to undergo surgery as assessed by a head and neck physician.
- •Abnormal coagulation function:(PT > 16s,APTT>53s,TT> 21s, Fib < 1.5g/L), bleeding tendency, or currently on anticoagulant or thrombolytic therapy.
- •Severe heart disease, pulmonary dysfunction, patients with heart or lung function below Grade 3 (including Grade 3).
- •Laboratory values not meeting relevant criteria within 7 days prior to enrollment.
- •Previous use of anti-PD-1 antibodies, anti-PD-L1 antibodies,anti-PD-L2 antibodies, or anti-CTLA-4 antibodies (or any other antibodies targeting T cell co-stimulation or checkpoint pathways).
- •Pre-existing conditions requiring long-term use of immunosuppressive drugs or a need for systemic or local use of corticosteroids at immunosuppressive doses prior to enrollment.
- •HIV-positive individuals;HBsAg-positive individuals with positive HBV DNA copy number (quantitative test≥1000 cps/ml); positive chronic hepatitis C blood screening(HCV antibody positive).
- •Traditional herbal medicine used for anti-tumor purposes within 4 weeks before randomization.
- •Women of childbearing potential with a positive pregnancy test and breastfeeding women.
研究组 & 干预措施
Experimental group
Experimental
Patients with locally advanced operable head and neck squamous cell carcinoma
干预措施: Cetuximab (Drug)
Experimental group
Experimental
Patients with locally advanced operable head and neck squamous cell carcinoma
干预措施: Zimberelimab (Drug)
Experimental group
Experimental
Patients with locally advanced operable head and neck squamous cell carcinoma
干预措施: Docetaxel (Drug)
Experimental group
Experimental
Patients with locally advanced operable head and neck squamous cell carcinoma
干预措施: Cisplatin (Drug)
结局指标
主要结局
ORR
时间窗: 9 weeks
overall response rate
次要结局
- PCR(9 weeks)
- PFS(2 years)
- Adverse Events Graded By Ctcae V5.0(90 days after the first dose of study treatment)
- MPR(9 weeks)
- DCR(2 years)
- OS(5 years)
研究者
Xuekui Liu
Chief physician
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
未知
2 期
Phase II clinical trial of the third-line Cetuximab and irinotecan or Cetuximab therapy for patients with KRAS wild type unresectable/recurrent colorectal cancerColorectal CancerJPRN-UMIN000001963ational Cancer Center Hospital60
进行中（未招募）
不适用
Open-label, phase II, multicentre study on cetuximab treatment asfirst-line monotherapy in elderly patients with metastatic colorectalcancer expressing EGFREpidermal Growth Factor Receptor-expressing in metatstatic colorrectal cancer in first line treatment.EUCTR2004-001696-19-ESSpanish Cooperative Group for Gastrointestinal Tomour therapy40
招募中
2 期
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell CancerHead and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaNCT04375384Wake Forest University Health Sciences38
进行中（未招募）
1 期
Catumaxomab and chemotherapy in patients with recurrent ovarian cancerThis is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes in patients with recurrent epithelial ovarian cancer and punctuable ascites.MedDRA version: 15.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004585-15-DECharité - Universitätsmedizin Berlin51
进行中（未招募）
不适用
PHASE II STUDY WITH CETUXIMAB SINGLE AGENT FOLLOWED BY 5-FU, CETUXIMAB AND PELVIC RADIOTHERAPY AS NEO-ADJUVANT TREATMENT FOR OPERABLE, LOCALLY ADVANCED RECTAL CANCERCARCINOMA DEL TRATTO GASTROINTESTINALE, TESTA-COLLOMedDRA version: 6.1Level: PTClassification code 10038038EUCTR2005-000722-24-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA